Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMX-883 in AML and High-Risk MDS
NCT07723703Phase 1Recruiting
- Sponsor
- Amphista Therapeutics
- Start
- Sep 2026
- Primary completion
- Dec 2028
- Countries
- 2
01
Overview
Phase 1, open-label trial of AMX-883 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (3 arms), sponsored by Amphista Therapeutics. Primary endpoints: Adverse Events and Dose Limiting Toxicities. Started Sep 2026; status: recruiting.
02
Drugs
AMX-883
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07723703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07723703.